Characterizing Pulmonary Hypertension–Related Hospitalization Costs Among Medicare Advantage or Co
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
4
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
5
